learn Cyproterone
a synthetic anti-androgen and weak progestogen that inhibits DHT binding to androgen receptor
Search
forLearn
5 / 801 resultslearn Fluridil
a topical anti-androgen with less systemic involvement
learn Clascoterone
a novel topical treatment that inhibits DHT on androgen receptors
learn Celastrol
learn RU58841
a potent but unapproved and potentially problematic topical anti-androgen
Research
5 / 1000+ results
research Hormone Blocking Anticancer Drugs
The document explains how certain drugs block hormones to treat cancers like breast and prostate cancer.
research Enzalutamide/finasteride/goserelin/zoledronic-acid
research Emerging medication for the treatment of male hypogonadism
New treatments for male hypogonadism are effective and should be personalized.
research Suppression of spermatogenesis with desogestrel and testosterone pellets is not enhanced by addition of finasteride.
research FINASTERIDE AND PSA
Community Join
5 / 1000+ resultscommunity Why you should use 0.5mg Dut instead of 1mg Fin
The comparison of 0.5mg dutasteride and 1mg finasteride for treating hair loss in men with androgenetic alopecia, with discussion of which is more effective and has fewer side effects.
community Trestolone (MENT) as a nuclear treatment
Experimenting with trestolone as a treatment for hair loss in an attempt to avoid DHT-related treatments such as finasteride and dutasteride, and discussing the potential effects of its receptor selectivity on the androgen receptors in the scalp.
community A concern regarding the upcoming androgen degrader drug GT20029
GT20029 is a topical treatment that degrades androgen receptors to prevent hair thinning and loss, potentially offering fewer side effects than systemic treatments like finasteride. Concerns include its impact on hair texture and potential systemic effects, with market availability speculated in 3 to 5 years.
community FCE 28260: A Forgotten 5α-Reductase Inhibitor
FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.
community GT20029 - Promising phase II results
GT20029 showed significant hair growth and safety in phase II trials, with no adverse sexual events. Users are hopeful but concerned about future costs and systemic effects.